|
US6469158B1
(en)
|
1992-05-14 |
2002-10-22 |
Ribozyme Pharmaceuticals, Incorporated |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
|
US5804683A
(en)
|
1992-05-14 |
1998-09-08 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA with alkylamine
|
|
WO1995006731A2
(en)
|
1993-09-02 |
1995-03-09 |
Ribozyme Pharmaceuticals, Inc. |
Non-nucleotide containing enzymatic nucleic acid
|
|
US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
|
US6111086A
(en)
|
1998-02-27 |
2000-08-29 |
Scaringe; Stephen A. |
Orthoester protecting groups
|
|
ATE450621T2
(de)
|
2000-03-30 |
2009-12-15 |
Whitehead Biomedical Inst |
Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
|
|
KR100872437B1
(ko)
|
2000-12-01 |
2008-12-05 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
|
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
|
WO2003040395A2
(en)
|
2001-11-07 |
2003-05-15 |
Applera Corporation |
Universal nucleotides for nucleic acid analysis
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
US20090018097A1
(en)
|
2005-09-02 |
2009-01-15 |
Mdrna, Inc |
Modification of double-stranded ribonucleic acid molecules
|
|
JP2012504389A
(ja)
|
2008-09-22 |
2012-02-23 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッド |
修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法
|
|
EP3067359A1
(en)
|
2008-09-23 |
2016-09-14 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
|
EP2379083B1
(en)
|
2008-12-18 |
2017-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
WO2013063313A1
(en)
|
2011-10-25 |
2013-05-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
|
JP2016507484A
(ja)
|
2012-12-06 |
2016-03-10 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
ジスルフィドマスキングプロドラッグ組成物および方法
|
|
CA2921162A1
(en)
|
2013-05-01 |
2014-11-06 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US10150965B2
(en)
*
|
2013-12-06 |
2018-12-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
EP3152308A4
(en)
|
2014-06-06 |
2017-12-27 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having bioreversible and non-bioreversible groups
|
|
ES2747842T3
(es)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de doble hebra modificados por ligando
|
|
WO2016130806A2
(en)
*
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
CN114891053A
(zh)
|
2016-08-23 |
2022-08-12 |
迪克纳制药公司 |
包含可逆修饰的寡核苷酸的组合物及其用途
|
|
WO2018045317A1
(en)
|
2016-09-02 |
2018-03-08 |
Dicerna Pharmaceuticals, Inc. |
4'-phosphate analogs and oligonucleotides comprising the same
|
|
WO2018223081A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
MX2020000154A
(es)
*
|
2017-06-29 |
2020-07-22 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión de hmgb1.
|
|
UY38003A
(es)
*
|
2017-12-12 |
2019-06-28 |
Amgen Inc |
Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
KR20210102932A
(ko)
*
|
2018-12-10 |
2021-08-20 |
암젠 인크 |
Pnpla3 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
|
|
AU2020358016A1
(en)
*
|
2019-10-02 |
2022-04-21 |
Dicerna Pharmaceuticals, Inc. |
Chemical modifications of small interfering RNA with minimal fluorine content
|
|
WO2022221430A1
(en)
|
2021-04-14 |
2022-10-20 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating pnpla3 expression
|